Celularity signs on to do contract research for Regeneron
Celularity announced Tuesday morning that it will do contract research for Regeneron on the Tarrytown, NY-based company’s “off-the-shelf” CAR-T cell therapies. After a rough year, it’s another way for Celularity to fund its business.
Celularity declined to share the financial details of the contract. The initial focus of the work will be Regeneron’s gamma delta CAR-T cell therapy that is designed to attack solid tumors. Regeneron is partnered with Adicet Bio on Adicet’s gamma delta CAR-T therapy, which they’ve been collaborating on since 2016.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.